Inquire about the sustainability of 50%+ semi order growth and the timing of revenue conversion given AI demand.

Frank Laukien stated that semi orders are remarkable and accelerating, with sustainability expected for this year and next. He noted long lead times (3-8 quarters) mean revenue impact will be seen in Q4, FY27, and FY28, with good visibility. “We think this is very sustainable this year and next. And then I think the debate is whether it's sustainable at that pace in '28 and beyond... good visibility, but a little bit of a delayed gratification as more of -- some of that comes in, in Q4.”

Understand why Q2 organic revenue was lighter than expected, especially in BSI, and if any unusual events occurred.

Frank Laukien attributed the lighter revenue to a combined 110 bps impact from tariff refunds (on revenue growth) and lower-than-expected FX tailwind. The primary weakness was U.S. ACA/GOV revenues, down over $15 million year-over-year due to weak orders in H2 last year. “that combined effect was about 110 bps of growth rate... And the #1 and 2 and 3 reasons in our U.S. ACA/GOV,our U.S. ACA/GOV revenues in Q2 which is the result of weak orders in the second half of last year were down more than $10 million, actually more than $15 million still year-over-year.”

Questions on the margin ramp, benefits from pricing, input costs, the 250-300 bps margin expansion target, and FY27 cost actions.

Gerald Herman confirmed being on track for cost actions, with an additional $20 million expected in FY27 from the new operating structure. He reiterated the 250-300 bps operating margin expansion target for FY26. He noted pricing benefits from 2025 adjustments and emphasized volume as the biggest driver for Q4 performance. Input costs are currently baked into guidance. “On the cost actions, we're we're well on track. We're north of $140 million... that's going to contribute some more additional savings beyond the $140 million we are planning for in 2026... The biggest piece, I'd say, for the fourth quarter performance is really going to be above volume.”

BRKR

Bruker (BRKR) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 4, 2026

Source: earnings call transcript

Executive summary

Bruker Q2 FY26 — Return to Organic Growth and Strong Deep Tech Orders

Bruker returned to organic revenue growth in Q2 FY26, driven by strong demand in deep tech and biopharma, despite continued weakness in U.S. academic markets and China revenue declines. The company delivered significant margin expansion and EPS growth, benefiting from cost reduction initiatives and tariff refunds. Management expects continued profitability improvements and double-digit EPS growth in FY26 and FY27, supported by a strong order book and a new operating structure.

Highlights

Returned to organic revenue growth of 2.8% in Q2 FY26, or 3.4% excluding tariff refunds.
Scientific Instruments segment achieved 10% organic bookings growth year-over-year, with book-to-bill above 1.0 for the fourth consecutive quarter.
Deep tech semiconductor tools and energy research technologies saw over 50% organic order growth year-over-year in Q2.
Non-GAAP diluted EPS increased 53% to $0.49 in Q2 FY26, driven by cost reductions and tariff refunds.
Achieved $30 million in cost savings in Q2, on track for $140 million annualized savings in FY26.

Concerns

U.S. academic orders remained weak in Q2, with U.S. ACA/GOV revenues down more than $15 million year-over-year.
Asia Pacific revenue declined in the low double digits percentage in Q2, including a low double-digit decline in China.
Q2 FY26 reported revenues were at the low end of expectations, unfavorably impacted by tariff refunds (on revenue growth) and a stronger U.S. dollar.
Non-GAAP effective tax rate increased to 25% from 23.6% in Q2 FY25.
GAAP results include a noncash goodwill impairment charge of $135 million related to automation and spatial biology businesses.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Reported Revenue	$3.54 billion to $3.57 billion high materiality	FY26	High
Full-year 2026 Organic Revenue Growth	1% to 2% year-over-year high materiality	FY26	High
Full-year 2026 Acquisitions Contribution to Growth	1.5% medium materiality	FY26	High
Full-year 2026 Non-GAAP Operating Margin Expansion	250 to 300 basis points year-over-year high materiality	FY26	High
Full-year 2026 Non-GAAP EPS	$2.10 to $2.15 high materiality	FY26	High
Q3 FY26 Organic Revenue	roughly flat to up slightly year-over-year medium materiality	Q3 · FY26	Medium
Q3 FY26 Operating Margins and EPS	slight sequential decrease medium materiality	Q3 · FY26	Medium
Q4 FY26 Organic Revenue Growth, Operating Margin, and EPS	meaningful sequential and year-over-year increases high materiality	Q4 · FY26	High
FY27 Additional Cost Reductions	$20 million medium materiality	FY27	High
FY27 Margin Growth	well above 100 bps medium materiality	FY27	Medium
FY27 Non-GAAP EPS Growth	double-digit, hopefully, mid-teens high materiality	FY27	Medium
Long-term Operating Margin Target	drive back towards a 20% EBIT operating margin as quickly as possible and then more gradually move up to the low 20s in EBIT and mid-20s in EBITDA high materiality	Long-term	High
Q4 FY26 Revenue Expectation	around the $1 billion range high materiality	Q4 · FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
BioSpin Group H1 FY26 revenue. Saw strong revenue growth in hospital clinical and biopharma, offset by weakness in China, ACA/GOV, food testing, and automation. NMR preclinical and preclinical imaging had robust order growth (double digits in H1).	$393 million	down mid-single digits percentage	—	—
CALID Group H1 FY26 revenue. Driven by mass spectrometry, including the Tofwork acquisition. Saw strength in biopharma, security detection, and European ACA/GOV, partially offset by weaker revenues in the U.S. Molecular Diagnostics solid H1 revenue growth, microbiology roughly flat.	$627 million	increased in the mid-single-digit percentage	—	—
Bruker Nano H1 FY26 revenue. Saw weakness in ACA/GOV industrial markets, while weakness in U.S. ACA/GOV funding continued to impact spatial biology. This was largely offset by robust strength in semiconductor metrology due to AI-driven orders.	$507 million	low single-digit percentage decline	—	—
BEST (Bruker Energy and Supercon Technologies) H1 FY26 revenue growth, net of intercompany eliminations. Strong growth in the superconductor business and solid revenue growth at Research Instruments (RRI). RRI secured very strong multiyear orders for Fusion Energy and high-energy physics technologies in H1.	—	up 6%	—	—

Risks & headwinds

U.S. Academic Funding Weakness Q2 FY26, ongoing impact from H2 FY25 orders.

U.S. ACA/GOV revenues down more than $15 million YoY in Q2 FY26.

Mitigation:Expectation of eventual NIH outlays translating into orders, with potential Q3 budget flush leading to Q4 bookings.

Asia Pacific / China Revenue Decline Q2 FY26.

Asia Pacific revenue declined low double digits percentage in Q2 FY26, including a low double-digit decline in China.

Mitigation:China ACA/GOV orders were up >20% in Q2, suggesting potential future revenue recovery with a typical 6-month delay.

Goodwill Impairment Charge Q2 FY26.

Noncash goodwill impairment charges of $135 million.

Mitigation:Related to automation and spatial biology businesses which continued to experience operating losses; implies ongoing challenges in these specific business areas.

FX Headwind FY26, particularly Q3 and Q4.

Foreign exchange tailwind to revenues reduced from 1.5% to 0.5% for FY26, turning into a revenue headwind in Q3 and Q4, with about $15 million impact in Q3.

Mitigation:Guidance updated to reflect FX rates as of June 30, 2026.

Supply Chain Challenges Current.

Not quantified.

Mitigation:Some challenges around componentry (electronics side), but management is comfortable it's baked into current guidance.

What to watch in Q3 FY26

U.S. Academic & Government (ACA/GOV) Orders

Q3 FY26 and beyond

Current still weak in Q2, revenues down >$15 million YoY

Target Improvement in order intake, especially from NIH outlays and Q3 budget flush.

Why it matters

U.S. ACA/GOV is a significant market; recovery in orders would boost overall growth and indicate broader market health.

U.S. academic orders still remained weak in Q2... We will observe what's happening in Q3 and, of course, the Q3 budget flush, which seems to be underway, could, for us, also mean decent Q4 U.S. ACA/GOV bookings.

Find out whether BRKR delivers this. Inve re-checks your case every morning.

Q&A highlights

Clarify how tariff refunds are treated (pass-through vs. profit) and their embedding in H2/FY guidance.

Gerald Herman explained that some tariff elements were contra-revenue, but refunds added ~200 bps to Q2 operating margins and $0.06 to EPS. The H2 impact was already factored into original guidance, just pulled forward to Q2.

“with respect to EPS, we've also indicated that, that generated roughly 200 basis points of margin expansion in the quarter for the second quarter. As far as the second half goes, we've already factored that or baked that into our earlier guide numbers.”

asked by Puneet Souda · answered by Gerald Herman

2 min read 5 chapters

Detailed narrative

Strategic Reorganization for Integrated Workflows

Bruker implemented a new operating structure effective July 1, 2026, combining its BioSpin, Daltonics, and Optics divisions into a new Bruker Biosystems group. This reorganization aims to address the growing need for scientific integration in the post-genomic era, connecting complementary life science research workflows for comprehensive disease biology insights.

The new structure is expected to drive an additional $20 million in cost reductions in fiscal year 2027, enhancing group-level agility and investment prioritization for innovation.

Strong Deep Tech Order Growth

The company experienced robust order growth in its deep tech areas, with semiconductor metrology and energy research technologies seeing over 50% organic order growth in Q2 FY26. These proprietary capabilities, including security detection systems, are valuable as life science research demand recovers.

These orders, often with 9-24 month lead times, are expected to benefit Q4 FY26 and significantly contribute to revenue and P&L in FY27 and beyond, indicating strong sustainability and visibility for the next 6+ quarters.

Cost Reduction and Margin Expansion

Bruker made significant progress on cost actions, realizing $30 million in Q2 FY26 and remaining on track for $140 million in annualized cost savings for FY26. This focus on cost reductions, combined with favorable mix and volume, drove a 350 basis point increase in non-GAAP gross margin to 52.1% and a 510 basis point increase in non-GAAP operating margin to 14.1% in Q2.

The company aims for continued margin expansion and double-digit EPS growth in FY26 and FY27, targeting a 20% EBIT operating margin long-term.

Geographic and End-Market Dynamics

While Americas and European revenues grew approximately 10% organically in Q2 FY26, Asia Pacific revenue declined in the low double digits, including China. U.S. academic orders remained weak, impacting spatial biology, but were offset by strength in biopharma, security detection, and European academic markets.

China orders for ACA/GOV were up over 20% in Q2, suggesting a potential revenue recovery in future quarters, reflecting a typical 6-month delay between orders and revenue.

Q4 FY26 Revenue and Margin Setup

Management anticipates a strong Q4 FY26 with meaningful sequential and year-over-year increases in organic revenue growth, operating margin, and EPS. This is attributed to a shift of approximately $20 million in semiconductor customer delivery requirements from Q3 to Q4, the expected delivery of ultra-high field systems, and a favorable mix and higher volume.

The company expects Q4 revenue to be around $1 billion, supported by a strong backlog and seasonal trends.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.